ABSTRACT
BACKGROUND: The findings from studies on the relationship between aldehyde dehydrogenases(ALDH) gene Glu504Lys polymorphism and colorectal cancer(CRC) were inconsistent. OBJECTIVES: The aim of this meta-analysis was to assess ALDH gene Glu504Lys polymorphism and CRC risk. METHODS: All of the relevant studies were identified from PubMed and Embase database. Statistical analyses were conducted with STATA 12.0 software. Odds ratio (OR) with 95% confidence interval (CI) values were applied to evaluate the strength of the association. Nine studies with 2779 cases and 4533 controls were included. RESULTS: No significant variation in CRC risk was detected in any of the genetic models overall. To explore the sources of heterogeneity,we performed further sub-group analyses by ethnicity and quality assessment of these studies. In the sub-group analysis by race, significant associations between ALDH gene Glu504Lys polymorphism and CRC risk were found in China(Glu/Lys vs Glu/Glu: OR = 0.70, 95%CI = 0.57-0.85; the dominant model: OR =0.69, 95%CI =0.48-0.98) and Japan(Lys/Lys vs Glu/Glu:OR =0.72, 95%CI =0.55-0.95). CONCLUSION: This meta-analysis suggests that the ALDH2 Glu504Lys polymorphism may be associated with susceptibility to CRC. Furthermore, large and well-designed studies are needed to confirm these conclusions.
Subject(s)
Aldehyde Dehydrogenase, Mitochondrial/genetics , Aldehyde Dehydrogenase/genetics , Colorectal Neoplasms/enzymology , Colorectal Neoplasms/genetics , Polymorphism, Genetic/genetics , Aldehyde Dehydrogenase, Mitochondrial/metabolism , Asian People/genetics , China , Genetic Predisposition to Disease , Humans , Polymorphism, Single Nucleotide , Risk FactorsABSTRACT
ObjectiveTo evaluate the efficacy and safety of tolterodine tartrate in treating patients with early overactive bladder(OAB) symptoms after transurethral resection prostate (TURP).Methods Thirty-one patients who received TURP and were found OAB at recent follow-up were enrolled and divided by random digits table method into study group ( 16 cases) and control group ( 15 cases).The patients in study group were treated with 2 mg tolterodine tartrate twice a day for four weeks,while the changes of OAB in control group were observed.The OAB symptoms score (OABSS),maximum flow rate(Qmax),24 h urination and adverse reactions during the period of medication of two groups before and after treatment were recorded and observed.Results The second evaluation,all the indexes except Qmax in study group improved significantly compared with those of the first evaluation in study group and control group the second evaluation.The indexes included urination times[(6.8 ± 1.0) times vs.( 12.5 ± 1.5) times,(11.8 ± 1.2)times],urgency times[(1.4 ± 1.1) times vs.(4.1 ±2.2) times,(4.1 ±2.3) times],urine volume [(214 ±36) ml vs.( 177 ± 46) ml,( 178 ± 44) ml ],nocturia times [ ( 1.9 ± 0.7) times vs.(2.9 ± 1.3 ) times,(2.8 ±1.4) times ],urge incontinence times [ (0.6 ± 0.5 ) times vs.( 1.6 ± 1.0) times,( 1.5 ± 1.0) times ].OABSS in study group the second evaluation was significantly lower than that in the first evaluation in study group and the second evaluation in control group [ (3.6 ± 1.8 ) scores vs.( 7.6 ± 3.3 ) scores,(7.4 ± 3.2) scores,P ＜ 0.01 or ＜ 0.05 ].There was no statistical significance in all the indexes in control group between the first evaluation and the second evaluation (P ＞ 0.05).There were 2 cases with adverse reactions which performed as dry mouth which could be tolerant.ConclusionTolterodine tartrate is efficient and safe in treating patients with early OAB symptoms after TURP.
